Page 2 - THEALOZ DUO LEAFLET CONGRES 2021_Slide

FOR PA TIENTS WITH DR Y EYES
FOR PATIENTS WITH DRY EYES

OSE 3% | HY
TREHALOSE 3% | HYALURONIC ACID 0.15% MEDICAL DEVICE
TREHAL
AL
MEDIC
AL DEVICE
CID 0.15%
UR
ONIC A
A unique combination for ocular surface bioprotection

Hyaluronic Acid Trehalose

3
HYALURONIC ACID LUBRICATION TREHALOSE BIOPROTECTION ,
1
4
with LONG LASTING RELIEF 2 OSMOPROTECTION and
REGENERATION 5,6
PROTECTION, HYDRATATION AND LUBRICATION OF THE EYE,
FOR TREATMENT OF MODERATE TO SEVERE DRY EYE SYNDROME

POSOLOGY
• 1 drop in each eye, from 4 to 6 times a day
• Suitable for contact lens wearers

1. Nakamura M et al. Characterisation of water retentative properties of hyaluronan. Cornea 1993; 12(6): 433-6.
2. Snibson et al. Ocular Surface Residence Times of Artificial Tears Solutions. Cornea 1998; 11(4): 288-293.
3. McCann LC et al. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea 2012; 31(1): 1-6.
4. Matsuo T. Trehalose protects corneal epithelial cells from death by drying. B J Ophthalmol. 2001; 85(5)610–12.
2 5. Aragona P et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren’s syndrome patients. Br J Ophthalmol 2002;
86: 879-884.
6. Baudouin C et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010 Jul; 29(4): 312-34.